FDA Grants Accelerated Approval to BMS's Zenbexus for Advanced Multiple Myeloma

Bristol Myers Squibb's Zenbexus has won accelerated approval from the U.S. Food and Drug Administration for advanced multiple myeloma, marking the debut of a new class of medicine for the blood cancer. The oral treatment is the first drug cleared by U.S. regulators using a more sensitive measure of remission. In other biotech news, pharmacy benefit managers (PB Ms) have agreed to display TrumpRx drug prices, embracing price comparisons under the program. Meanwhile, Novartis secured a key patent victory in the U.K. over its heart failure drug Entresto.